Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Source: View publication →
In singleton pregnancies at high risk for preterm preeclampsia, prophylactic low-dose aspirin (150 mg/day) administered from the first trimester to 36 weeks' gestation significantly reduced the incidence of the disease compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ASPRE trial provided definitive, high-quality evidence that early initiation (11-14 weeks) of 150 mg nightly aspirin drastically reduces preterm preeclampsia in high-risk women. It strongly supported the clinical utility of utilizing an advanced first-trimester combined multimarker screening algorithm over traditional demographic risk factors alone.
Historical Context
Prior to ASPRE, aspirin prophylaxis for preeclampsia yielded conflicting results, with many studies using lower doses (60-81 mg), initiating treatment after 16 weeks, and screening patients based solely on clinical history. Meta-analyses had hypothesized that earlier initiation (<16 weeks) at a higher dose might specifically prevent the most dangerous phenotype (preterm preeclampsia), prompting the targeted, precision-medicine design of the ASPRE trial.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of low-dose aspirin theoretically prevent the development of preeclampsia when initiated early in pregnancy?
Key Response
Preeclampsia involves abnormal placentation and an imbalance between vasodilatory prostacyclin and vasoconstrictive thromboxane A2. Low-dose aspirin irreversibly inhibits COX-1, preferentially decreasing platelet thromboxane A2 production while largely sparing endothelial prostacyclin. This promotes vasodilation and prevents microthrombi in the placental bed. Initiating treatment before 16 weeks gestation targets the critical period of secondary trophoblast invasion.
The ASPRE trial utilized a multiparametric algorithm to identify high-risk patients. How does this compare to the traditional clinical risk-factor-based approach for initiating aspirin prophylaxis, and what are the practical barriers to implementing the ASPRE algorithm?
Key Response
ACOG traditionally recommends aspirin based solely on maternal historical and clinical risk factors. The ASPRE trial utilized the Fetal Medicine Foundation algorithm, which combines biophysical markers like mean arterial pressure and uterine artery Doppler pulsatility index with biochemical markers like PAPP-A and PlGF. While highly sensitive, barriers to widespread implementation include the lack of universal access, cost, and need for specialized training in early uterine artery Doppler and PlGF testing.
The ASPRE trial demonstrated a significant reduction in preterm preeclampsia but not term preeclampsia. What are the pathophysiological implications of this distinction, and how does it influence patient counseling?
Key Response
This distinction supports the theory that preterm and term preeclampsia represent overlapping but distinct phenotypes. Preterm preeclampsia is strongly associated with defective deep placentation, which early aspirin therapy can modify. Term preeclampsia is often driven by maternal metabolic factors or the placenta simply outgrowing its vascular supply, which aspirin is less effective at preventing. Counseling must emphasize that aspirin reduces the risk of severe early disease requiring premature delivery, but does not eliminate the overall risk of developing preeclampsia at term.
The ASPRE trial used a dose of 150 mg of aspirin taken at night, whereas 81 mg is the most common low-dose formulation in the United States. How should clinicians adapt this evidence to their prescribing practices, and what is the risk of under-dosing?
Key Response
Evidence suggests a dose-response relationship where doses lower than 100 mg may be insufficient, particularly in patients with higher body mass indices. Clinicians must weigh the pragmatic approach of prescribing two 81 mg tablets to approximate the 150 mg ASPRE protocol versus sticking to the traditional single 81 mg tablet. Under-dosing runs the risk of failing to achieve the profound 62 percent risk reduction in preterm preeclampsia demonstrated in the trial. Furthermore, night-time administration was used in ASPRE and may have a more optimal effect on diurnal blood pressure rhythms.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ASPRE trial screened nearly 27,000 women to randomize approximately 1,700 high-risk participants. Evaluate the statistical and methodological trade-offs of using an enriched enrollment design with a proprietary screening algorithm versus a pragmatic, unselected population-based trial.
Key Response
Enriched enrollment maximizes the event rate in the placebo group, ensuring adequate statistical power for a specific primary outcome with a smaller randomized sample. However, the trade-off is reduced external validity. The findings cannot be directly extrapolated to unselected populations or to high-risk groups identified by simpler clinical criteria. Additionally, screening 27,000 patients to identify 1,700 highlights the low positive predictive value of the algorithm in the general population, which has implications for the cost-effectiveness and broad utility of the screening strategy.
How would you evaluate the potential bias introduced by the rate of non-adherence and loss to follow-up in the ASPRE trial, and does the intention-to-treat analysis sufficiently mitigate these concerns?
Key Response
While intention-to-treat analysis is the gold standard for preserving randomization and avoiding attrition bias, a high non-adherence rate in an intention-to-treat framework biases the effect estimate toward the null. The fact that ASPRE found a highly significant benefit despite some non-adherence suggests the true biological effect of 150 mg aspirin in fully adherent patients is even stronger. However, a rigorous editorial review would scrutinize whether the pill burden or side effect profile disproportionately affected specific demographic groups, which could limit the generalizability of the adherence rates.
Current USPSTF and ACOG guidelines recommend low-dose aspirin for pregnant individuals at high risk based primarily on maternal history. Based on the ASPRE trial, should guidelines be updated to mandate the combined screening algorithm and a 150 mg dose?
Key Response
Updating guidelines requires balancing the strong Level I evidence from ASPRE against real-world feasibility. Current history-based guidelines are highly accessible and zero-cost, whereas mandating the ASPRE protocol requires widespread, standardized access to uterine artery Dopplers and PlGF assays, which is currently unfeasible in many resource-limited settings. A pragmatic guideline update might provide a strong recommendation for the higher dose of aspirin in high-risk patients, while giving a conditional recommendation for the combined screening algorithm only in settings where the requisite resources and quality controls are available.
Clinical Landscape
Noteworthy Related Trials
CLASP Trial
Tested
Aspirin 60mg daily
Population
Pregnant women at high risk of preeclampsia or intrauterine growth restriction
Comparator
Placebo
Endpoint
Proteinuric preeclampsia, IUGR, or stillbirth
NICHD MFMU Network Aspirin Trial
Tested
Aspirin 60mg daily
Population
Women at high risk for preeclampsia due to chronic hypertension, diabetes, or previous preeclampsia
Comparator
Placebo
Endpoint
Incidence of preeclampsia
ASPIRIN Trial
Tested
Aspirin 81mg daily
Population
Nulliparous pregnant women in low-income and middle-income countries
Comparator
Placebo
Endpoint
Preterm birth before 37 weeks of gestation
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis